-
EP1357942
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1357942
| EP1357942 - METHODS AND COMPOSITIONS FOR TREATMENT OF IMMUNE DYSFUNCTION DISORDERS [Right-click to bookmark this link] | Status | The application has been refused Status updated on 01.04.2016 Database last updated on 25.09.2024 | Most recent event Tooltip | 01.04.2016 | Refusal of application | published on 04.05.2016 [2016/18] | Applicant(s) | For all designated states The Lauridsen Group Incorporated 2325 North Loop Drive, P.O. Box 645 Ames, IA 50010 / US | [2003/45] | Inventor(s) | 01 /
CAMPBELL, Joy, M. 2325 North Loop Drive P.O. Box 645 Ames, IA 50010 / US | 02 /
STROHBEHN, Ronald, E. 2325 North Loop Drive P.O. Box 645 Ames, IA 50010 / US | 03 /
WEAVER, ERIC, M. 2325 North Loop Drive P.O. Box 645 Ames, IA 50010 / US | 04 /
BORG, Barton, S. 2325 North Loop Drive P.O. Box 645 Ames, IA 50010 / US | 05 /
RUSSELL, Louis, E. 2325 North Loop Drive P.O. Box 645 Ames, IA 50010 / US | 06 /
POLO POZO, Francisco, Javier 2325 North Loop Drive P.O, Box 645 Ames, IA 50010 / US | 07 /
ARTHINGTON, John, D. 2325 North Loop Drive P.O. Box 645 Ames, IA 50010 / US | 08 /
QUIGLEY, James, D., III 2325 North Loop Drive P.O. Box 645 Ames, IA 50010 / US | [2003/45] | Representative(s) | Webber, Philip Michael Dehns St Bride's House 10 Salisbury Square London EC4Y 8JD / GB | [N/P] |
| Former [2003/45] | Webber, Philip Michael Frank B. Dehn & Co., 179 Queen Victoria Street London EC4V 4EL / GB | Application number, filing date | 02733789.8 | 29.01.2002 | [2003/45] | WO2002US02753 | Priority number, date | US20010264987P | 30.01.2001 Original published format: US 264987 P | US20010973284 | 10.09.2001 Original published format: US 973284 | [2003/45] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO02078742 | Date: | 10.10.2002 | Language: | EN | [2002/41] | Type: | A2 Application without search report | No.: | EP1357942 | Date: | 05.11.2003 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.10.2002 takes the place of the publication of the European patent application. | [2003/45] | Search report(s) | International search report - published on: | EP | 13.03.2003 | Classification | IPC: | A61K39/395, A61K39/00, A61P37/00, // (C07K16/06, 16:02, 16:04) | [2003/45] | CPC: |
A61K39/395 (EP,US);
A61K35/16 (EP,US);
A61K35/20 (EP,US);
A61K39/12 (EP,US);
A61K39/15 (EP,US);
A61K39/39 (EP,US);
A61P37/00 (EP);
C07K16/02 (EP,US);
C07K16/04 (EP,US);
C07K16/06 (EP,US);
C07K16/065 (EP,US);
A61K2039/505 (EP,US);
A61K2039/542 (EP,US);
C07K2317/77 (EP,US);
C12N2720/12334 (EP,US);
C12N2770/10034 (EP,US)
(-)
| Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2003/45] | Extension states | AL | 01.09.2003 | LT | 01.09.2003 | LV | 01.09.2003 | MK | 01.09.2003 | RO | 01.09.2003 | SI | 01.09.2003 | Title | German: | VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON IMMUNERKRANKUNGEN | [2003/45] | English: | METHODS AND COMPOSITIONS FOR TREATMENT OF IMMUNE DYSFUNCTION DISORDERS | [2003/45] | French: | PROCEDES ET COMPOSITIONS DESTINES AU TRAITEMENT DE DYSFONCTIONS IMMUNITAIRES | [2003/45] | Entry into regional phase | 01.09.2003 | National basic fee paid | 01.09.2003 | Designation fee(s) paid | 01.09.2003 | Examination fee paid | Examination procedure | 07.08.2002 | Request for preliminary examination filed International Preliminary Examining Authority: US | 01.09.2003 | Examination requested [2003/45] | 05.11.2003 | Amendment by applicant (claims and/or description) | 21.07.2006 | Despatch of a communication from the examining division (Time limit: M06) | 07.03.2007 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 17.05.2007 | Reply to a communication from the examining division | 24.06.2008 | Despatch of a communication from the examining division (Time limit: M06) | 05.01.2009 | Reply to a communication from the examining division | 27.09.2010 | Date of oral proceedings | 02.11.2010 | Despatch of communication that the application is refused, reason: substantive examination [2016/18] | 02.11.2010 | Minutes of oral proceedings despatched | 02.07.2015 | Application refused, date of legal effect [2016/18] | Appeal following examination | 11.01.2011 | Appeal received No. T1350/11 | 14.03.2011 | Statement of grounds filed | 02.07.2015 | Result of appeal procedure: appeal of the applicant was rejected | 02.07.2015 | Date of oral proceedings | 08.07.2015 | Minutes of oral proceedings despatched | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 21.07.2006 | Request for further processing for: | 17.05.2007 | Request for further processing filed | 17.05.2007 | Full payment received (date of receipt of payment) Request granted | 31.05.2007 | Decision despatched | Fees paid | Renewal fee | 05.05.2004 | Renewal fee patent year 03 | 20.01.2005 | Renewal fee patent year 04 | 27.01.2006 | Renewal fee patent year 05 | 29.01.2007 | Renewal fee patent year 06 | 25.01.2008 | Renewal fee patent year 07 | 30.01.2009 | Renewal fee patent year 08 | 25.01.2010 | Renewal fee patent year 09 | 25.01.2011 | Renewal fee patent year 10 | 25.01.2012 | Renewal fee patent year 11 | 25.01.2013 | Renewal fee patent year 12 | 27.01.2014 | Renewal fee patent year 13 | 27.01.2015 | Renewal fee patent year 14 | 27.01.2016 | Renewal fee patent year 15 | Penalty fee | Additional fee for renewal fee | 31.01.2004 | 03 M06 Fee paid on 05.05.2004 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]US4096244 (NEWSON FREEMAN OSWALD, et al) [X] 1,2,8-10,16,17,23 * column 1, lines 25-27 and lines 47-50; column 2, lines 21-26; column 2, lines 51-54; column 2, lines 65-68; column 4, lines 3-8; column 5, lines 24-64 *; | [X]GB2013691 (STOLLE RES & DEV) [X] 1,4,8,9,12,16,19,23 * page 2, lines 44-54; page 3, lines 19-21; page 3, lines 48-53; page 5, lines 38-58; pages 7-9 *; | [X]DE19504755 (TSOLKAS PANAGIOTIS [DE], et al) [X] 1,3,8,9,11,16,18,23 * the whole document *; | [X]WO9814209 (OVIMMUNE INC [US]) [X] 1,3,7-9,11,15,16,18,22,23 * claims; page 16; page 3, line 37-page 4, line 2; page 11, lines 17-24; page 13, lines 26-31; page 5, line 17 *; | [X]US5871731 (SPROTTE GUENTER [DE], et al) [X] 1-5,8-13,16-20,23 * column 1, lines 54-61; column 2, line 46-column 3, line 51; examples *; | [E]WO0226258 (RES CORP TECHNOLOGIES INC [US]) [E] 1,2,8-10,16,17,23* claims; pages 8-11 *; | [E]WO0228430 (WEISBART RICHARD [US], et al) [E] 1,2,8-10,16,17,23 * pages 3, 5, and 7; claims *; | [X] - WOLF H M ET AL, "The anti-inflammatory effect of an oral immunoglobulin (IgA-IgG) preparation and its possible relevance for the prevention of necrotizing enterocolitis.", ACTA PAEDIATRICA SUPPLEMENT, (1994), no. 396, ISSN 0803-5326, pages 37 - 40, XP001119976 [X] 1,2,8-10,16,17,23 * the whole document * | [X] - CONRAD ET AL, "Compartment-specific accumulation of recombinant immunoglobulins in plant cells: an essential tool for antibody production and immunomodulation of physiological functions and pathogen activity", PLANT MOLECULAR BIOLOGY, NIJHOFF PUBLISHERS, DORDRECHT, NL, (199809), vol. 38, ISSN 0167-4412, pages 101 - 109, XP002135721 [X] 6,14,21 * abstract * DOI: http://dx.doi.org/10.1023/A:1006029617949 | Examination | - BENTWICH Z. ET AL, "Immune activation in the context of HIV infection.", CLINICAL AND EXPERIMENTAL IMMUNOLOGY JAN 1998 LNKD- PUBMED:9472654, (199801), vol. 111, no. 1, ISSN 0009-9104, pages 1 - 2 | - FELDMANN MARC, "Many cytokines are very useful therapeutic targets in disease.", THE JOURNAL OF CLINICAL INVESTIGATION NOV 2008 LNKD- PUBMED:18982159, (200811), vol. 118, no. 11, ISSN 0021-9738, pages 3533 - 3536 | - ELLIOTT M.J. ET AL, "Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.", ARTHRITIS AND RHEUMATISM DEC 1993 LNKD- PUBMED:8250987, (199312), vol. 36, no. 12, ISSN 0004-3591, pages 1681 - 1690 | - DAVIDSON N.J., "The therapeutic potential of anti-cytokine antibodies in the treatment of chronic inflammatory disease.", EXPERT OPINION ON INVESTIGATIONAL DRUGS JUL 1998 LNKD- PUBMED:15992019, (199807), vol. 7, no. 7, ISSN 1744-7658, pages 1115 - 1120 | - BRENCHLEY JASON M. ET AL, "Microbial translocation is a cause of systemic immune activation in chronic HIV infection.", NATURE MEDICINE DEC 2006 LNKD- PUBMED:17115046, (200612), vol. 12, no. 12, ISSN 1078-8956, pages 1365 - 1371 | - AUKRUST P. ET AL, Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters., THE JOURNAL OF INFECTIOUS DISEASES FEB 1994 LNKD- PUBMED:7906293, VOL. 169, NR. 2, PAGE(S) 420 - 424, (199402), ISSN 0022-1899 |